Telix Pharmaceuticals (TLX) Debt Ratio (2023 - 2026)
Telix Pharmaceuticals (TLX) posted quarterly Debt Ratio of 0.38 for Q4 2024, up 1565.86% year-over-year from 0.02 in Q1 2024, and up 1565.86% quarter-over-quarter from 0.02 in Q4 2023.
Powered by 
Analysis
Telix Pharmaceuticals (TLX) Debt Ratio (2023 - 2026) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Debt Ratio for 2 consecutive years, with 0.38 the latest figure, recorded in Q4 2024.
- In Q4 2024, Debt Ratio rose 1565.86% year-over-year to 0.38; the TTM figure through Dec 2024 stood at 0.38 (up 1565.86% YoY), while the FY2024 annual figure was 0.38, up 1565.86% from the prior year.
- Debt Ratio grew to 0.38 in Q4 2024 per TLX's latest filing, from 0.02 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.38 in Q4 2024 and bottomed at 0.02 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Telix Pharmaceuticals | 4.03 Bn | 3.74 Bn | - | 0.38 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.38 |
| Dec 31, 2025 | 0.35 |
| Dec 31, 2024 | 0.38 |
| Dec 31, 2023 | 0.02 |